The global varicose veins treatment devices market size was valued at around USD 1.1 billion in 2018 and is expected to expand at a CAGR of 6.3% over the forecast period. Increasing demand for minimally invasive procedures to treat varicose veins, along with growing investments by the market players to develop innovative and effective products is likely to boost the growth.
Varicose veins can be aesthetically displeasing. They become problematic only in case they cause pain, aching, swelling, and considerable discomfort. In severe cases, they may rupture and can lead to ulcers. Available options for the treatment of this condition have evolved over the last few years. The majority of private healthcare providers are offering improved minimally invasive techniques.
The elderly population is more prone to the development of varicose veins. The effect of aging on the structure and functions of the veins is found to be considerable. Over the age of 50, one out of every two people is affected by varicose veins. Overweight people and pregnant women are also susceptible to developing this condition. Some of the treatments available in the market include sclerotherapy, laser therapy, and radiofrequency ablation. Of these, sclerotherapy is preferred as a first-line of treatment for varicose, spider, and reticular veins.
Varicose vein's surgical procedures are likely to undergo significant changes shortly. Surgery has been largely replaced by noninvasive options. Due to the risk of infections associated with invasive surgeries, preference for noninvasive surgeries has increased in recent years. This factor is projected to drive the varicose veins treatment devices market during the forecast period.
In addition to the risk of infection, noninvasive methods also involve minimum hospital stays, thus saving time and cost. More surgeons are adopting foam sclerotherapy, endovenous laser treatment, and radiofrequency ablation over conventional surgical practices.
Sclerotherapy is a non-invasive technique that involves injecting a foam sclerosant in the veins. It is less painful as it does not involves cutting veins. The recovery of patients is faster as it does not require hospital admission. Moreover, in the U.S., Medicare provides coverage to patients undergoing sclerotherapy treatment. In 2016, more than 375,000 sclerotherapy procedures were conducted in the U.S. Insurance coverage can increase the adoption of sclerotherapy in the forthcoming years.
Sclerotherapy segment accounted for the largest market share in 2018 due to various advantages of this treatment including less bruising and scarring; no need for sedation; no need for a prolonged hospital stay, simple follow-up treatments, and positive reimbursement policies. The usage of foam Sodium Tetradecyl Sulfate (STS) in sclerotherapy has innovated the treatment and provides long-term success.
Various organizations such as the British Association of Sclerotherapies (BAS) undertake initiatives annually for raising awareness and encouraging the adoption of various treatments. An increasing number of approvals is also contributing to the market growth. In February 2015, the Food and Drug Administration (FDA) reviewed data for the premarket approval of the VenaSeal system. The FDA approval for the VenaSeal system included an analysis of results from three clinical studies. Medtronic announced that new CPT codes may aid in getting positive coverage for its VenaSeal closure device from the public and private insurers in the U.S. in November 2017.
The endovenous ablation segment is likely to witness the fastest growth over the forecast period. The endovenous ablation procedure is preferred over the conventional procedures such as surgical stripping and ligation, as the procedure is minimally invasive and is associated with lesser complications. Moreover, various market players are focusing on the development of efficient and technologically advanced products which is likely to boost the market growth.
North America led the market in terms of revenue share in 2018 as it has a large population base, which is aesthetically conscious. People are willing to undergo cosmetic procedures owing to the evident results and safety. North America is an early adopter of technology and the demonstration of safety and efficacy of laser treatments has helped reduce the stigma attached to cosmetic procedures and has helped gain social acceptance for laser procedures, especially by men.
The introduction of advanced technology is also boosting the growth of the market for varicose vein treatment devices. In May 2016, Navarro opened a vein center in the U.S. with a vision to educate the community about chronic venous insufficiency and varicose veins and the proper treatment for this condition. About 30 million Americans suffer from varicose veins each year and less than 10% of the population seeks treatment.
In the U.S., the Society for Vascular Surgery has created clinical care guidelines along with the American Venous Forum for the treatment of varicose veins. These guidelines offer recommendations for the management of chronic venous diseases, based on the grading system. Grading of the severity of the condition helps care and insurance providers communicate with one another. For instance, while referring patients to vein specialists, a general physician can effectively communicate the severity. Patients can be classified into different groups based on their severity.
The Asia Pacific is expected to be the fastest-growing segment in the forthcoming years due to the presence of a large elderly population, increasing disposable income, and rising awareness about these procedures. The market is highly diverse due to varying regulatory factors, which result in the difference in the availability of products in different countries.
Some of the key market players are AngioDynamics, Inc.; Medtronic plc; Syneron Medical Ltd.; Biolitec AG; Lumenis Ltd.; Energist Group; Eufoton SRL; Quanta Systems S.p.A.; and Teleflex, Inc. The leading company in terms of revenue was Medtronic, followed by Teleflex, Inc. The higher revenue growth of these companies can be attributed to the broad product portfolio, higher penetration at the global level, and various strategic initiatives.
For instance, Medtronic developed VenaSeal Closure System and received the U.S. FDA approval in February 2015 and insurance coverage in 2017. Hence, the development of innovative products, commercialization, and availability of reimbursements for the product are some of the major strategies adopted by the market players to maintain their dominance.
In February 2017, Teleflex acquired Vascular Solutions, Inc. for about USD 1 billion. This acquisition was expected to boost the vascular and interventional access product portfolios of the former through additional revenue associated with the peripheral and coronary vascular market of Vascular Solutions.
Furthermore, one of the key strategies implemented by some of the market players is to purchase products directly from their respective manufacturers to sell them as a distributor. For instance, AngioDynamics, Inc. purchased Sotradecol from Bioniche Pharma Group Limited in 2006 and Asclera from Merz in March 2016.
In March 2018, Medtronic launched an Investigation Device Exemption (IDE) study to determine the effectiveness and safety of the Abre venous self-expanding stent system to be used in the treatment of deep venous diseases. Around 200 subjects are likely to be enrolled in this study across 35 locations throughout the U.S. and Europe.
In November 2017, Biolitec AG declared successful results of the long-term study (FiLaC therapy) performed on LEONARDO Mini laser with Radial 2ring laser therapy to treat varicose veins. The company observed good results in first-line therapy (64.1%) and even better in the second-line treatment cure rates (85.5%).
Report Attribute |
Details |
The market size value in 2020 |
USD 1.3 billion |
The revenue forecast in 2025 |
USD 1.7 billion |
Growth Rate |
CAGR of 6.3% from 2019 to 2025 |
The base year for estimation |
2018 |
Historical data |
2014 – 2017 |
Forecast period |
2019 – 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2025 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Japan; China; India; Brazil; Mexico; South Africa |
Key companies profiled |
AngioDynamics, Inc.; Medtronic plc; Syneron Medical Ltd.; Biolitec AG; Lumenis Ltd.; Energist Group; Eufoton SRL; Quanta Systems S.p.A.; Teleflex, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global varicose veins treatment devices market report based on type and region:
Type Outlook (Revenue, USD Million, 2014 - 2025)
Endovenous Ablation
Endovenous Laser Therapy
Radiofrequency Ablation
Sclerotherapy
Surgical Ligation & Stripping
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
U.K.
Germany
France
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
b. The global varicose vein treatment devices market size was estimated at USD 1.2 billion in 2019 and is expected to reach USD 1.3 billion in 2020.
b. The global varicose vein treatment devices market is expected to grow at a compound annual growth rate of 6.3% from 2018 to 2025 to reach USD 1.7 billion by 2025.
b. North America dominated the varicose vein treatment devices market with a share of 46.3% in 2019. This is attributable to the early adoption of technology and the demonstration of safety and efficacy of laser treatments that have helped reduce the stigma attached to cosmetic procedures.
b. Some of the key market players are AngioDynamics, Inc.; Medtronic plc; Syneron Medical Ltd.; Biolitec AG; Lumenis Ltd.; Energist Group; Eufoton srl; Quanta Systems S.p.A.; and Teleflex, Inc.
b. Increasing demand for minimally invasive procedures to treat varicose veins, along with growing investments by the market players to develop innovative and effective products is likely to boost the growth.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.